| 2.18 0.03 (1.4%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.73  |
1-year : | 2.88 |
| Resists | First : | 2.34 |
Second : | 2.47 |
| Pivot price | 2.2 |
|||
| Supports | First : | 2.14 |
Second : | 1.78 |
| MAs | MA(5) : | 2.17 |
MA(20) : | 2.23 |
| MA(100) : | 2.33 |
MA(250) : | 2.4 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.8 |
D(3) : | 12.4 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 3.44 | Low : | 2.08 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XBIT ] has closed above bottom band by 35.4%. Bollinger Bands are 13.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.18 - 2.19 | 2.19 - 2.2 |
| Low: | 2.11 - 2.13 | 2.13 - 2.14 |
| Close: | 2.16 - 2.18 | 2.18 - 2.2 |
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Thu, 03 Sep 2026
XBiotech (NASDAQ:XBIT) Shares Cross Below 200-Day Moving Average - Time to Sell? - MarketBeat
Mon, 24 Aug 2026
XBiotech (XBIT) Quarter in Focus: Reported EPS Misses Expectations for This Review; Closing Move - dars.gov.et
Tue, 11 Aug 2026
XBiotech (XBIT) Edges Higher at $2.28 as Stock Consolidates Between Key Support and Resistance - Rip Sell Trade - dars.gov.et
Mon, 15 Jun 2026
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - GlobeNewswire
Mon, 21 Jul 2025
ETFs Investing in XBiotech, Inc. Stocks - TradingView
Mon, 19 May 2025
XBIT Forecast — Price Prediction for 2026. Should I Buy XBIT? - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 24.3 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 333 (K) |
| Shares Short P.Month | 281 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | -30 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -1.48 |
| PEG Ratio | 0 |
| Price to Book value | 0.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.64 |
| Dividend | 2.5 |
| Forward Dividend | 0 |
| Dividend Yield | 114.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|